Powered by

It's a case of déjà vu as Alzheon pulls IPO again

Jan 17, 2019 - FierceBiotech

Alzheimer's drug developer Alzheon has pulled plans for a public listing on the Nasdaq for the second time in nine months.

The biotech—which has a small-molecule drug for Alzheimer's in early clinical testing—told the SEC yesterday that it had decided to withdraw its latest IPO prospectus, originally filed last August, which sought to raise $30 million though the sale of 6 million shares at a range of $4 to $6.

Alzheon also had a tentative attempt at a larger, up to $80 million-p...